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OBJECTIVE — To evaluate metabolic effects of sex steroids in nonfasting and fasting condi-
tions, independent from changes in body composition.
RESEARCHDESIGNANDMETHODS — Arandomizedclinicaltrialwasperformedto
create contrasting sex steroid levels in healthy young men: by letrozole (aromatase inhibitor) to
lower estradiol (E2) and increase testosterone (group T, n  10) versus letrozole plus E2 patches
tolowerTandraiseE2(groupE,n10).Mixedmealsandhyperinsulinemic-euglycemicclamps
were performed before and after a 1-week treatment period.
RESULTS — Following intervention, the postprandial triglyceride response displayed a di-
vergingresponsewithadeclineingroupTandanincreaseingroupE;thepostprandialglucose-
dependent insulinotropic polypeptide (GIP) response increased in group T. Insulin sensitivity
increased in group T but remained unaltered in group E.
CONCLUSIONS — In healthy young men, short-term changes in sex steroids affect post-
prandial triglyceride and GIP response and insulin sensitivity.
Diabetes Care 33:1831–1833, 2010
L
ow testosterone has been shown to
be a strong predictor of metabolic
syndromeinmenaged20–40years,
although underlying biological mecha-
nisms are poorly understood (1,2). Typi-
cally, low testosterone in the presence of
disturbed glucose metabolism is com-
bined with high estradiol (E2) (3). Modi-
fying steroid levels into low E2 and high
testosterone, by an aromatase inhibitor
(AI) reducing conversion of testosterone
into E2 through aromatase (P450a), re-
sults in decreased fasting glucose and in-
sulin levels in young men (4). Yet,
nonfasting conditions might be relevant
as well since humans spend the majority
of time in this state, which might better
predict cardiovascular risk (5). In the
present study, short-term sex steroid ef-
fects were explored in both fasting and
nonfasting conditions; men were ran-
domly treated with an AI to lower E2 and
increase testosterone (group T) or an AI
and E2 patches to lower testosterone and
raise E2 (group E). E2 patches in men
cause downregulation of testosterone se-
cretion through the feedback mechanism
of the hypothalamic-pituitary-gonadal
axis. A week is supposed to be sufﬁcient
to reach a steady state.
RESEARCH DESIGN AND
METHODS— Twenty healthy young
men (aged 20–40 years) were random-
ized to receive either 2.5 mg letrozole
(Femara; Novartis, Basel, Switzerland)
(group T, n  10) or letrozole plus
Dermestril,exemption75g/day(Besins,
Brussels, Belgium) (group E, n  10). All
subjects gave written informed consent
and completed the trial, which was ap-
proved by the ethical review board of the
GhentUniversityHospital,conductedac-
cording to the principles of the Declara-
tion of Helsinki and registered at
clinicaltrials.gov (NCT00740194).
Measurements before and after a
1-week treatment period were performed
in similar conditions, starting at 0800 h
after overnight fasting and a 10-min bed
rest at the hospital. Hyperinsulinemic-
euglycemic clamps were initiated by a
primed-continuous insulin infusion and
ﬁxed at 40 mIU/m
2
body surface area/min
throughout the 120-min clamp to com-
pletelysuppressendogenousglucosepro-
duction (6). The insulin infusion rate was
similar in both groups. Variable infusion
of glucose, adjusted every 5 min, was
used to maintain euglycemia (5 mmol/l).
Venous blood was arterialized through
retrograde cannulation of a wrist vein
while heating the hand at 60–70°C using
a custom-made heating box. The glucose
disposal rate (insulin sensitivity; M value)
was measured during the last 30 min and
corrected for lean body mass (dual-
energy X-ray absorptiometry). Thirty
minutesaftertheclamp,astandardmixed
meal (bread, margarine, cheese, and
milk), providing a caloric content of
1,000 kcal (45% fat, 36% carbohydrates,
and 19% proteins), was served and blood
samplesweretakenbeforeand10,30,60,
120, 180, 240, and 300 min after inges-
tion. Triglycerides, glucose, and C-
peptide serum concentrations were
determined using standard laboratory as-
says(modularimmunoassay;RocheDiag-
nostics, Penzberg, Germany). Intra- and
interassaycoefﬁcientsofvariationforall
parameters were 3 and 6%, respec-
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used to determine serum E2 (Incstar,
Stillwater, MN), testosterone, and sex
hormone–binding globulin (Orion Di-
agnostica, Espoo, Finland). Total gluca-
gon-like peptide-1 and intact glucose-
dependent insulinotropic polypeptide
were determined as previously described
(7). Apart from standard statistical analy-
ses, longitudinal mixed-effects modeling
wasusedtoassessdifferencesinpostmeal
responses and were performed using the
SPSS 12.0 software package (SPSS, Chi-
cago, IL) and SAS 9.1.3 (SAS Institute,
Cary, North Carolina).
RESULTS— All subjects were Cauca-
sian, and no anthropometric differences
were observed between both groups (age
34  7 and 31  5 years; BMI 22.4  2.4
and 23.4  2.2 kg/m
2; waist-to-hip ratio
0.87  0.05 and 0.86  0.04, group T
and E, respectively) (Table 1).
Sex steroid changes
Following intervention, E2 levels de-
creased by 56% and testosterone levels
increasedby114%ingroupT,whereasin
group E, testosterone levels declined by
44%andtotalE2levelsincreasedby43%.
Adverse events or side effects did not
occur.
Nonfasting measurements
Following intervention, postprandial re-
sponses of glucose, C-peptide, and gluca-
gon-like peptide 1 remained unchanged,
though triglycerides displayed a diverg-
ing response, declining in group T and
increasing in group E, and the glucose-
dependent insulinotropic polypeptide re-
sponse increased in group T.
Fasting measurements
Following intervention, no differences in
fasting glucose, insulin levels, or triglyc-
eridelevelswererevealed.Yet,anincrease
ininsulinsensitivity(MvalueLBM)wasob-
servedingroupT,whereasnochangewas
observed after intervention in group E.
The observation remained similar when
adjusting for mean glucose levels during
steady state (data not shown; P  0.018).
CONCLUSIONS— The study shows
thatshort-termchangesinsexsteroidsaf-
fect glucose and lipid metabolism in fast-
ing and nonfasting conditions in healthy
young men.
Concomitantly increasing testoster-
one and decreasing E2 levels has positive
effects on both postprandial triglyceride
handling and insulin sensitivity. Effects
on postprandial triglyceride handling are
inlinewithpreviousreports(8)andseem
relevant for metabolic risk (9). The im-
provement in insulin sensitivity explains
our previous ﬁndings of reduced fasting
glucose and insulin levels after 4 weeks of
AI in young men (4) and corroborates a
former report (10) showing acute reduc-
tion in insulin sensitivity 2 weeks after
discontinuing testosterone replacement
in hypogonadal men. It remains unclear
whether these observations result from
changes in lipid metabolism or altered
postreceptor insulin signaling in muscle
(11)andwhetherimprovedinsulinsensi-
tivity enhances muscle lipid uptake (12).
Further, this same intervention increased
postprandial glucose-dependent insuli-
notropic polypeptide (GIP) response,
thoughfutureresearchisneededtoestab-
lish metabolic consequences. Effects of
sex steroids on GIP have not been re-
portedbefore.ActionofGIPisnotlimited
topancreaticcellsandmayaffectlipidho-
meostasis (13) and intestinal glucose
transport (14).
The hormonally contrasting group
withdecreasedtestosteroneandrelatively
highE2levelsdisplayedalargerpostpran-
dial triglyceride response without effects
on insulin sensitivity, though possible ef-
fectsmighthavebeenmaskedduetovari-
ation in transdermal delivery of E2. These
ﬁndings were demonstrated in a limited
Table 1—A 1-week hormonal intervention and effects on postprandial and fasting metabolic parameters in healthy young men
Sex steroids
Group T (letrozole only) (n  10) Group E (letrozole  E2 patches) (n  10)
Before After P value* Before After P value*
Testosterone (ng/dl) 495  138 988  137 0.001 425  137 246  127 0.001
Free testosterone (ng/dl) 8.8  2.0 21.5  4.9 0.001 9.5  2.2 5.3  2.7 0.001
Sex hormone–binding globulin (nmol/l) 41  18 39  16 0.11 32 (22–40) 32 (26–43) 0.33
Estradiol (pg/ml)† 20.5 (16.8–23.0) 8.9 (8.5–9.4) 0.005 16.3 (15.1–19.8) 19.4 (15.9–41.3) 0.059
Free E2 (pg/ml)† 0.37 (0.30–0.42) 0.18 (0.17–0.19) 0.005 0.30 (0.28–0.38) 0.36 (0.28–0.76) 0.074
Postprandial response
Glucose response (mg/dl/min)‡ 1.20 1.25 0.11 1.20 1.19 0.65
C-peptide response (ng/ml/min)‡ 0.070 0.069 0.71 0.070 0.069 0.62
Glucagon-like peptide 1 response
(pM/min)‡ 0.57 0.59 0.55 0.57 0.60 0.37
GIP response (pM/min)‡ 1.19 1.24 0.047 1.19 1.17 0.37
Triglyceride response (mg/dl/min)‡ 0.50 0.44 0.036 0.50 0.54 0.010
Fasting measurements
Glucose (mg/dl) 0.88  0.15 0.84  0.08 0.40 0.84  0.06 0.86  0.12 0.56
Insulin (IU/l)† 5.1 (3.2–8.7) 4.3 (2.5–7.1) 0.17 5.0 (3.7–8.4) 5.8 (4.5–7.2) 0.58
Triglycerides (mg/dl)† 79 (61–139) 75 (56–92) 0.12 82 (56–140) 81(70–145) 0.68
Euglycemic-hyperinsulinemic clamp
Mean glycemic level (mmol/l) 5.1  0.27 4.9  0.15 0.11 4.9  0.27 4.9  0.15 0.70
GIR (ml/h) 167  65 199  65 0.051 194  53 194  49 0.99
M valueLBM (mol/min/kgLBM) 51.3  21.5 61.3  21.9 0.042 60.4  16.4 60.3  14.5 0.99
Data are means  SD or median (1st–3rd quartile) in case of non-Gaussian distribution. *According to paired Student t test. †According to Wilcoxon signed-rank
test. ‡Longitudinal mixed-effects modeling.
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tatingconﬁrmationandextensiontopop-
ulations at risk (those who are obese,
thosewithdisturbedglucosemetabolism,
andtheelderly)toevaluatepotentialclin-
ical implications (e.g., related to lipid
handling or buffering of adipocytes for
prevention of lipotoxicity) (9,13,15).
In summary, changing sex steroid
levels in a largely physiological range in-
ﬂuences postprandial triglyceride han-
dling, GIP, and insulin sensitivity in
healthy young men. Given the short term
of this intervention, these effects can be
assumed to occur independently from
changes in body composition.
Acknowledgments— This study was sup-
portedinpartbygrantG0066207oftheFlem-
ish Fund for Scientiﬁc Research (FWO
Vlaanderen).
No potential conﬂicts of interest relevant to
this article were reported.
B.L. researched data and wrote the manu-
script. M.O. reviewed/edited the manuscript.
L.M.H. contributed to discussion. B.W. re-
searched data. J.J.H. researched data and
reviewed/edited the manuscript. G.T. contrib-
uted to discussion and reviewed/edited the
manuscript. J.-M.K. reviewed/edited the
manuscript. J.B.R. researched data and re-
viewed/edited the manuscript.
The authors are indebted to Dr. S. Van-
steelandt, Ghent University, Belgium, for
statistical consulting, as well as to the em-
ployees of the Department of Endocrinol-
ogy, Kaatje Toye, Bea Vervinckt, and Nera
Steyaert, for the meticulous realization of
the study protocol. We thank Inge Boc-
quaert and Kathelijne Mertens for perform-
ing the immunoassays. We also thank Eric
Matthys for using his skills to create the cus-
tom-made heating box. We thank all volun-
teers who participated as study subjects.
References
1. Haring R, Vo ¨lzke H, Felix SB, Schipf S,
Do ¨rr M, Rosskopf D, Nauck M, Scho ¨ﬂ
C, Wallaschofski H. Prediction of met-
abolic syndrome by low serum testos-
terone levels in men: results from the
study of health in Pomerania. Diabetes
2009;58:2027–2031
2. Khaw KT, Barrett-Connor E. Lower endog-
enous androgens predict central adiposity
in men. Metabolism Ann Epidemiol 1992;
2:675–682
3. Colangelo LA, Ouyang P, Liu K, Kopp P,
Golden SH, Dobs AS, Szklo M, Vaidya D,
Cushman M, Gapstur SM. Association of
endogenous sex hormones with diabetes
and impaired fasting glucose in men:
multi-ethnic study of atherosclerosis. Di-
abetes Care 2009;32:1049–1051
4. Lapauw B, T’Sjoen G, Mahmoud A, Kauf-
man JM, Ruige JB. Short-term aromatase
inhibition: effects on glucose metabolism
and serum leptin levels in young and el-
derly men. Eur J Endocrinol 2009;160:
397–402
5. Lin HJ, Lee BC, Ho YL, Lin YH, Chen CY,
Hsu HC, Lin MS, Chien KL, Chen MF.
Postprandial glucose improves the risk
prediction of cardiovascular death be-
yond the metabolic syndrome in the non-
diabetic population. Diabetes Care 2009;
32:1721–1726
6. Ferrannini E, Mari A. How to measure in-
sulin sensitivity. J Hypertens 1998;16:
895–906
7. Deacon CF, Holst JJ. Immunoassays for
the incretin hormones GIP and GLP-1.
Best Pract Res Clin Endocrinol Metab
2009;23:425–432
8. AgledahlI,SkjmrpePA,HansenJB,Svart-
berg J. Low serum testosterone in men is
inversely associated with non-fasting se-
rum triglycerides: the Troms° study. Nutr
Metab Cardiovasc Dis 2008;18:256–262
9. Ruige JB, Van Gaal LF. Low fasting tri-
glycerides: hallmark of the healthy large
hip? Obesity (Silver Spring) 2009;17:
1621–1626
10. Yialamas MA, Dwyer AA, Hanley E, Lee
H, Pitteloud N, Hayes FJ. Acute sex
steroid withdrawal reduces insulin sensi-
tivity in healthy men with idiopathic hy-
pogonadotropic hypogonadism. J Clin
Endocrinol Metab 2007;92:4254–4259
11. BelfortR,MandarinoL,KashyapS,Wirfel
K, Pratipanawatr T, Berria R, Defronzo
RA, Cusi K. Dose-response effect of ele-
vatedplasmafreefattyacidoninsulinsig-
naling. Diabetes 2005;54:1640–1648
12. Ukropcova B, McNeil M, Sereda O, de
Jonge L, Xie H, Bray GA, Smith SR. Dy-
namic changes in fat oxidation in human
primary myocytes mirror metabolic char-
acteristics of the donor. J Clin Invest
2005;115:1934–1941
13. Song DH, Getty-Kaushik L, Tseng E, Si-
mon J, Corkey BE, Wolfe MM. Glucose-
dependent insulinotropic polypeptide
enhances adipocyte development and
glucose uptake in part through Akt
activation. Gastroenterology 2007;133:
1796–1805
14. Singh SK, Bartoo AC, Krishnan S, Boylan
MO, Schwartz JH, Michael Wolfe M. Glu-
cose-dependent insulinotropic polypep-
tide (GIP) stimulates transepithelial
glucose transport. Obesity (Silver Spring)
2008;16:2412–2416
15. Frayn KN. Adipose tissue as a buffer for
daily lipid ﬂux. Diabetologia 2002;45:
1201–1210
Lapauw and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 1833